Table 3.
Biomarker differences over a 12 month period between patients with heart failure with preserved ejection fraction without and with diabetes
| Biomarker | % change (95% CI) a | Trend | |||
|---|---|---|---|---|---|
| n | Non‐DM | DM | P b | Adj c P | |
| eGFR (mL/min/1.73 m2) | 225 | −14% (−17, −10) | −14% (−18, −10) | 0.38 | 0.34 |
| UPCR (mg/mmol) | 187 | −2% (−14, +10) | −6%, (−20, +11) | 0.20 | 0.10 |
| Urinary protein level (mg/dL) | 187 | −4% (−19, +12) | −2% (−20, +20) | 0.20 | 0.24 |
| hs‐CRP (mg/L) | 183 | +1% (−5, +3) | −11% (−27, +7) | 0.74 | 0.54 |
| Uric acid (mg/dL) | 188 | −1% (−5, +3) | +0% (−5, +6) | 0.12 | 0.23 |
| NT‐proBNP (pg/mL) | 189 | −2% (−12, +10) | −5% (−21, +13) | 0.90 | 0.48 |
| hs‐TnT (ng/mL) | 189 | −1% (−14, +13) | +11% (−3, +27) | 0.06 | 0.016 |
| sST2 (ng/mL) | 188 | −1% (−7, +5) | −4% (−9, +2) | 0.54 | 0.60 |
| Aldosterone (ng/L) | 200 | +17% (+9, +26) | +23% (+14, +33) | 0.58 | 0.76 |
| PICP (ng/mL) | 164 | +6% (−5, +18) | +5% (−6, +18) | 0.22 | 0.10 |
| CITP (ng/mL) | 78 | −25% (−45, +2) | −19% (−38, +6) | 0.77 | 0.89 |
| PIIINP (ng/mL) | 168 | +8% (−1, +18) | +10% (+1, +20) | 0.11 | 0.15 |
| MMP‐2 (ng/mL) | 203 | −0% (−4, +4) | −3% (−7, +1) | 0.59 | 0.72 |
| MMP‐9 (ng/mL) | 203 | −6% (−13, +3) | −1% (−11, +10) | 0.23 | 0.35 |
| TIMP‐1 (ng/mL) | 203 | −1% (−4, +2) | −2% (−5, +2) | 0.67 | 0.59 |
| Gal‐3 (ng/mL) | 189 | +6% (+3, +10) | +9% (+4, +14) | 0.27 | 0.52 |
CI, confidence interval; CITP, collagen type I; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; Gal‐3, galectin‐3; hs‐CRP, high‐sensitivity C‐reactive protein; hs‐TnT, high‐sensitivity troponin T; MMP‐2, matrix metalloproteinase 2; MMP‐9, matrix metalloproteinase 9; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; PICP, pro‐collagen type I carboxy‐terminal peptide; PIIINP, pro‐collagen type III amino‐terminal peptide; sST2, soluble ST2; TIMP‐1, tissue inhibitor of metalloproteinase 1; UPCR, urinary protein to creatinine ratio.
Change in geometric means estimated via linear regression after log transformation.
Adjusted for baseline value of biomarker only.
Additionally adjusted for age, gender, strata, and treatment group (spironolactone vs. placebo per Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist randomization).